Recardio's Positive Phase 2 Results Presented as Latebreaker at World Congress on Acute Heart Failure 2022 in Madrid
23 mai 2022 14h00 HE
|
Recardio Inc.
SAN FRANCISCO, May 23, 2022 (GLOBE NEWSWIRE) -- Entitled "Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptinin Combination with Filgrastim in Early...
Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)
13 janv. 2022 07h00 HE
|
Gritstone bio
-- Phase 2/3 GRANITE-CRC-1L trial has registrational intent -- -- Updated data from Phase 1/2 trial in end-stage metastatic MSS-CRC further support the association of circulating tumor DNA (ctDNA)...
uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B
09 déc. 2021 07h05 HE
|
uniQure Inc.
~ Largest gene therapy study in hemophilia B achieved primary endpoint of non-inferiority in annualized bleeding rate after stable Factor IX (FIX) expression, assessed at 18 months following a single...
Daten aus Phase-3-Studie von Pfizer und BioNTech zeigen hohe Wirksamkeit von COVID-19-Auffrischungsimpfung
21 oct. 2021 06h45 HE
|
BioNTech SE
Die ersten Ergebnisse einer randomisierten, kontrollierten COVID-19 Impfstoff-Auffrischungsstudie zeigen eine relative Impfstoffwirksamkeit von 95,6 % gegen COVID-19 in einem Zeitraum, in dem Delta...
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine
21 oct. 2021 06h45 HE
|
BioNTech SE
First results from any randomized, controlled COVID-19 vaccine booster trial demonstrate a relative vaccine efficacy of 95.6% against disease during a period when Delta was the prevalent strain In...
Adocia’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China
14 oct. 2021 01h30 HE
|
Adocia SA
This Phase 3 clinical program will enroll over 1,300 people with diabetes and is expected to be pivotal for product registration in ChinaFirst patient in the study will trigger a milestone payment to...
Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial of AXS-12 in Narcolepsy
16 sept. 2021 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Bone Therapeutics fait le point sur l’avancement de ses études cliniques
19 juil. 2021 01h00 HE
|
Bone Therapeutics SA
INFORMATION RÉGLEMENTÉE Les premiers résultats de la phase III évaluant JTA-004 sont prévus pour la première moitié de septembre La phase IIb évaluant ALLOB est en cours malgré un...
Bone Therapeutics provides update on the progress of clinical studies
19 juil. 2021 01h00 HE
|
Bone Therapeutics SA
REGULATED INFORMATION JTA-004 Phase III top-line results planned first half September ALLOB Phase IIb currently on track but recruitment slow due to COVID-19 pandemic Gosselies,...
Arcutis Announces First Patient Enrolled in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Seborrheic Dermatitis
12 juil. 2021 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Topical roflumilast potential “Best-in-Class” topical PDE4 inhibitorSeborrheic dermatitis affects 10 million patients in the U.S.Potential first new topical treatment for seborrheic dermatitis in...